Hypogonadism, Malignant Testicular Germ Cell Tumor
Conditions
Brief summary
This study evaluates 7 Tesla (T) magnetic resonance imaging (MRI) in observing changes in the brain (neuroimaging) in testicular cancer patients who have decreased testosterone (hypogonadism) and are on testosterone (androgen) replacement therapy. Symptoms of hypogonadism can include fatigue, weakness, loss of libido, depression, poor concentration and erectile dysfunction. Some patients experience mental changes after diagnosis and treatment. There is some evidence that hypogonadism produces structural changes in the brain. The 7T MRI uses radio waves and a very powerful magnet linked to a computer to create detailed pictures of areas inside the body. This study may help researchers learn if 7T MRI can produce better images to assess the changes in the brain structure of testicular patients with hypogonadism and on androgen replacement therapy (ART).
Detailed description
PRIMARY OBJECTIVE: I. To assess longitudinal structural changes in brain architecture using MRI in hypogonadal men with testis cancer being treated with androgen replacement therapy. OUTLINE: This is an observational study. Patients undergo 7T MRI over 1-2 hours at baseline and at 12 months after baseline. Patients also undergo a proctored cognitive assessment over approximately 1 hour prior to each MRI. Additionally, patients undergo blood sample collection at screening and at 12 months after baseline MRI.
Interventions
PROCEDURE7 Tesla Magnetic Resonance Imaging
Undergo 7T MRI
PROCEDUREBiospecimen Collection
Undergo blood sample collection
PROCEDURECognitive Assessment
Undergo cognitive assessment
Sponsors
University of Southern California
National Cancer Institute (NCI)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Males age \>= 18 years * Diagnosed with germ cell tumor of the testis (seminoma or non-seminoma) and treated with radical orchiectomy * Diagnosed with hypogonadism and started androgen replacement therapy 6 months prior (+/- 2 weeks) * Ability to understand and the willingness to sign a written informed consent * Ability to undergo imaging procedure without any form of sedation
Exclusion criteria
* History of any neuropsychiatric disease * History of narcotic use or psychiatric medications * History of ART prior to current ART regimen * Standard contraindications for MRI: * Prior work as a machinist or metal worker, or history of metal being removed from the eyes * Cardiac pacemaker or internal pacing wires * Non-MRI compatible vena cava filter, vascular aneurysm clip, heart valve, spinal or ventricular shunt, optic implant, neuro-stimulator unit, ocular implant, or intrauterine device, or * Claustrophobia, or uncontrollable motion disorder * Current active second malignancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Brain structural connectivity | At baseline and 12 months | Measured using T1-weighted and diffusion tensor magnetic resonance imaging (MRI). |
| Brain functional connectivity | At baseline and 12 months | Measured using resting-state functional MRI. |
| Brain metabolic profiles | At baseline and 12 months | Evaluated by MR spectroscopy. |
| Brain perfusion | At baseline and 12 months | Evaluated by arterial spin labeling MRI. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORMark S Shiroishi, MD
University of Southern California
Outcome results
None listed